EDIT
Editas Medicine Inc
$
3.080
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
3.170
Open
2.450
VWAP
2.99
Vol
7.75M
Mkt Cap
276.95M
Low
2.440
Amount
23.17M
EV/EBITDA(TTM)
--
Total Shares
82.24M
EV
69.87M
EV/OCF(TTM)
--
P/S(TTM)
4.89
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
5.00M
+8096.72%
-0.311
-58.47%
6.34M
-79.28%
-0.223
-59.39%
1.69M
-63.66%
-0.357
-61.23%
Estimates Revision
The market is revising Upward the revenue expectations for Editas Medicine, Inc. (EDIT) for FY2025, with the revenue forecasts being adjusted by 23.66% over the past three months. During the same period, the stock price has changed by 123.19%.
Revenue Estimates for FY2025
Revise Upward
+23.66%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+2.53%
In Past 3 Month
Stock Price
Go Up
+123.19%
In Past 3 Month
11 Analyst Rating
1.95% Upside
Wall Street analysts forecast EDIT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EDIT is 3.14 USD with a low forecast of 1.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
1 Sell
Moderate Buy
1.95% Upside
Current: 3.080
Low
1.00
Averages
3.14
High
4.00
1.95% Upside
Current: 3.080
Low
1.00
Averages
3.14
High
4.00
Baird
Outperform -> NULL
downgrade
$8 -> $4
2025-05-13
Reason
Baird
Price Target
$8 -> $4
2025-05-13
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Editas Medicine to $4 from $8 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its IP update provided incremental newsflow.
Evercore ISI Group
Liisa Bayko
Buy
Maintains
$7 → $5
2024-12-16
Reason
Evercore ISI Group
Liisa Bayko
Price Target
$7 → $5
2024-12-16
Maintains
Buy
Reason
JP Morgan
Brian Cheng
Hold
to
Sell
Downgrades
n/a
2024-12-16
Reason
JP Morgan
Brian Cheng
Price Target
n/a
2024-12-16
Downgrades
Hold
to
Sell
Reason
RBC Capital
Luca Issi
Hold
Maintains
$5 → $4
2024-12-13
Reason
RBC Capital
Luca Issi
Price Target
$5 → $4
2024-12-13
Maintains
Hold
Reason
Barclays
Gena Wang
Hold
Maintains
$5 → $3
2024-12-13
Reason
Barclays
Gena Wang
Price Target
$5 → $3
2024-12-13
Maintains
Hold
Reason
Barclays lowered the firm's price target on Editas Medicine to $3 from $5 and keeps an Equal Weight rating on the shares. The company's restructuring update included reni-cel discontinuation with no commercial partner identified and a workforce reduction including the chief medical officer, the analyst tells investors in a research note. The firm says the reprioritizing resets Editas Medicine's development phase by years.
Chardan Capital
Geulah Livshits
Strong Buy
to
Hold
Downgrades
n/a
2024-12-13
Reason
Chardan Capital
Geulah Livshits
Price Target
n/a
2024-12-13
Downgrades
Strong Buy
to
Hold
Reason
Chardan analyst Geulah Livshits downgraded Editas Medicine to Neutral from Buy and withdrew the firm's price target after the company announced a strategic transition to focus entirely on development of in vivo therapies after failing to find a partner for its clinical-stage ex vivo-edited sickle cell and beta thalassemia therapy, reni-cel. With reni-cel deal upside now ruled out and limited details on the in vivo pipeline, the firm moves to the sidelines pending "further visibility on potential near-term value inflection points."
See All Ratings
Valuation Metrics
The current forward P/E ratio for Editas Medicine Inc (EDIT.O) is -1.77, compared to its 5-year average forward P/E of -6.02. For a more detailed relative valuation and DCF analysis to assess Editas Medicine Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.02
Current PE
-1.77
Overvalued PE
-0.40
Undervalued PE
-11.64
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.61
Current EV/EBITDA
0.04
Overvalued EV/EBITDA
1.37
Undervalued EV/EBITDA
-8.59
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
64.40
Current PS
14.31
Overvalued PS
129.48
Undervalued PS
-0.69
Financials
Annual
Quarterly
FY2025Q2
YoY :
+597.47%
3.58M
Total Revenue
FY2025Q2
YoY :
-64.59%
-25.46M
Operating Profit
FY2025Q2
YoY :
-21.26%
-53.24M
Net Income after Tax
FY2025Q2
YoY :
-23.17%
-0.63
EPS - Diluted
FY2025Q2
YoY :
-17.08%
-50.21M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+105.86%
-526.81
FCF Margin - %
FY2025Q2
YoY :
-88.71%
-1.49K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
42.7K
USD
5
3-6
Months
40.4K
USD
3
6-9
Months
4.5K
USD
2
0-12
Months
7.1K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 500.44% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
42.7K
USD
5
3-6
Months
40.4K
USD
3
6-9
Months
4.5K
USD
2
0-12
Months
7.1K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
EDIT News & Events
Events Timeline
2025-08-12 (ET)
2025-08-12
16:09:33
Editas Medicine reports Q2 EPS (63c), consensus (38c)
2025-06-12 (ET)
2025-06-12
05:09:14
Editas says levels of HBG1/2 promoter editing in hematopoietic stem cells
2025-05-14 (ET)
2025-05-14
07:29:12
Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs
Sign Up For More Events
Sign Up For More Events
News
9.5
08-12SeekingAlphaPinnedEditas Medicine GAAP EPS of -$0.63 misses by $0.25, revenue of $3.58M beats by $1.78M
5.0
06-20SeekingAlphaGene editors steady despite latest leadership shake-up at FDA
8.5
06-18BenzingaEli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst
Sign Up For More News
People Also Watch
NUKK
Nukkleus Inc
4.430
USD
+3.26%
IMPP
Imperial Petroleum Inc
3.000
USD
-0.66%
AXTI
AXT Inc
2.180
USD
-2.24%
PROV
Provident Financial Holdings Inc
15.450
USD
+0.32%
KNDI
Kandi Technologies Group Inc
1.320
USD
+0.76%
GSIT
GSI Technology Inc
3.200
USD
-2.74%
FBRX
Forte Biosciences Inc
10.570
USD
-1.77%
ABOS
Acumen Pharmaceuticals Inc
1.270
USD
+0.79%
SUNS
Sunrise Realty Trust Inc
10.780
USD
+1.41%
CRDL
Cardiol Therapeutics Inc
1.110
USD
-1.77%
FAQ
What is Editas Medicine Inc (EDIT) stock price today?
The current price of EDIT is 3.08 USD — it has increased 34.5 % in the last trading day.
What is Editas Medicine Inc (EDIT)'s business?
What is the price predicton of EDIT Stock?
What is Editas Medicine Inc (EDIT)'s revenue for the last quarter?
What is Editas Medicine Inc (EDIT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Editas Medicine Inc (EDIT)'s fundamentals?
How many employees does Editas Medicine Inc (EDIT). have?